Full-Time

Senior Manager

Business Operations, Research

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$158k - $198k/yr

Senior

San Carlos, CA, USA

This is a hybrid position, indicating that some in-office presence is required.

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
Risk Management
Requirements
  • BS/BA degree in related discipline and at least 5 years of related experience.
  • Previous experience in operational excellence, R&D operations, project management or similar operations role in a biotech/pharmaceutical organization.
  • Strong interpersonal and communication skills to interact daily with diverse cross-functional internal and external stakeholders.
  • Excellent organizational skills, detail-minded, results-oriented, and driven to complete projects on time with high quality.
  • Strong computer proficiency with MS Office suite, video conferencing tools, and document archiving systems.
Responsibilities
  • Independently manage cross-functional business process improvement initiatives and operational excellence projects, with positive impact to business continuity.
  • Lead meetings & workshops for cross-functional improvement projects; coordinate with Functional Representatives to ensure delivery of project strategy, goals, and timelines.
  • Partner with cross-functional stakeholders to foster collaborative problem-solving.
  • Identify potential risks and issues impacting the success of initiatives and partners cross-functionally to develop mitigation strategies to address them.
  • Think creatively about how to streamline processes and communication flows to improve the overall effectiveness to optimize the capacity of the Research organization.
  • Maintain comprehensive project documentation, including project charters, plans, and reports.
  • Create and manage timeline driven workplans, as well as creating visual process flow documentation (e.g. cross-functional process maps) that supports the work.
  • Take a creative approach to audience-facing reporting and documentation, establishing templates for use by others as needed.
  • Mentor and support the development of other PPAM Business Operations Team Members.
  • Able to thrive in a fluid environment and generate clarity in ambiguous situations.
  • Manage and maintain communications with stakeholders in a proactive and timely manner.
  • Actively contribute to infrastructure & growth within PPAM Business Operations.
Desired Qualifications
  • Advanced capability with MS Office software (Excel, PowerPoint, Word) is preferred.
  • Experience with the use of diagramming software (e.g. Visio, LucidCharts) is a plus.
  • Experience with the use of project or resource management tools (e.g. Smartsheet) and/or dashboard platforms is a plus.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a unique Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective, targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

11%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.